Entrada Therapeutics (TRDA) said Monday it has received authorization from UK regulators to start a phase 1/2 multiple ascending dose study of ENTR-601-44 for the potential treatment of certain types of Duchenne muscular dystrophy.

The study will consist of two parts, with part A evaluating safety, pharmacokinetics, and pharmacodynamics in about 24 patients using doses from 6 mg/kg to 18 mg/kg every six weeks. Part B will further evaluate the optimal dose established in part A, the company said.

The authorization follows the completion of a phase 1 study in which ENTR-601-44 showed a favorable safety profile with no serious adverse events, or changes in trends of vital signs, the company said.

The study is expected to begin in Q2, the biopharmaceutical company said.

Price: 13.50, Change: +0.06, Percent Change: +0.45